4507.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 08:15):

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...

Stats
Dagens volum	309 800
Gjennomsnittsvolum	1.04M
Markedsverdi	2 042.99B
EPS	¥0 ( 2024-01-30 )
Neste inntjeningsdato	( ¥135.09 ) 2024-05-07
Last Dividend	¥75.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.96
ATR14	¥2.65 (0.04%)

Volum Korrelasjon

Lang: -0.29 (neutral)

Kort: 0.02 (neutral)

Signal:(43.974) Neutral

Shionogi & Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shionogi & Co., Ltd. Korrelasjon - Valuta/Råvare

-0.30
( neutral )

-0.48
( neutral )

0.07
( neutral )

0.05
( neutral )

0.73
( moderate )

Shionogi & Co., Ltd. Økonomi

Annual	2022
Omsetning:	¥426.68B
Bruttogevinst:	¥364.44B (85.41 %)
EPS:	¥621.31

FY	2022
Omsetning:	¥426.68B
Bruttogevinst:	¥364.44B (85.41 %)
EPS:	¥621.31

FY	2022
Omsetning:	¥335.14B
Bruttogevinst:	¥279.72B (83.47 %)
EPS:	¥378.75

FY	2021
Omsetning:	¥297.18B
Bruttogevinst:	¥244.65B (82.33 %)
EPS:	¥365.03

Financial Reports:

No articles found.

Shionogi & Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥60.00 (N/A)	¥0 (N/A)	¥75.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Shionogi & Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.36 - Increase likely (47.28%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.25	2000-03-28
Last Dividend	¥75.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥1 157.25	--
Avg. Dividend % Per Year	0.00%	--
Score	4.44	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.36
Div. Directional Score	9.88	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

4.44

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8068.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
7350.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6590.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5936.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4617.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3852.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3093.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
1967.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
9531.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8424.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.363	1.500	2.73	4.10	[0 - 0.5]
returnOnAssetsTTM	0.114	1.200	6.21	7.46	[0 - 0.3]
returnOnEquityTTM	0.132	1.500	9.64	10.00	[0.1 - 1]
payoutRatioTTM	0.288	-1.000	7.12	-7.12	[0 - 1]
currentRatioTTM	6.57	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.74	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.47	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00724	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	14.19	1.000	5.85	5.85	[3 - 30]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00826	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.859	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.332	1.000	5.35	5.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	13.06	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.313	0.800	-1.249	-0.999	[0.5 - 2]
Total Score				12.39

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.87	1.000	8.70	0	[1 - 100]
returnOnEquityTTM	0.132	2.50	9.77	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.16	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.288	1.500	7.12	-7.12	[0 - 1]
pegRatioTTM	3.69	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.302	1.000	4.94	0	[0.1 - 0.5]
Total Score				7.36

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.